Abstract
Background:
Benign prostatic hypertrophy is the nonmalignant, uncontrolled growth of prostatic epithelial cells and stroma that, left untreated, may lead to difficult urination and other complications. A common treatment of BPH is lipid extract from saw palmetto fruit, and lipid extract from Cuban Royal palm (a palm of the same family) fruit is being studied for this use. One study found that the latter, D-004, at 100 to 400 mg/kg daily prevented prostatic hypertrophy (PH) induced with testosterone (T) in a rat model.
Objectives:
This study comprised 2 experiments in a rat model. The first assessed the effects of different doses of D-004 on T-induced PH; the second investigated the effects of D-004 on PH induced with dihydrotestosterone (DHT).
Methods:
In experiment 1, rats were distributed in 6 groups of 10 rats each. One group received an SC injection of soy oil and oral treatment with Tween 65/water vehicle (negative control). The other 5 groups received an SC injection of T 3 mg/kg daily and oral treatment with vehicle (positive control) or D-004 at 50, 200, 400, or 800 mg/kg daily suspended in vehicle. In experiment 2, rats were distributed in 3 groups of 10 rats each. A negative control group received treatment as in experiment 1. Positive controls received an SC injection of DHT 1.5 mg/kg and vehicle orally. The third group received an SC injection of DHT and oral treatment with D-004 at 800 mg/kg suspended in vehicle. All treatments were given for 14 days. At sacrifice, prostates were removed and weighed. Mean prostatic weights and prostatic/body weight ratios were calculated.
Results:
In experiment 1, in the groups receiving D-004 at 200, 400, or 800 mg/kg daily, prostatic weight was significantly lower compared with the positive control group (P < 0.05, P < 0.01, and P < 0.001, respectively); this effect was not seen in the group receiving 50 mg/kg daily. In the groups receiving D-004 at 400 and 800 mg/kg daily, prostatic/body weight ratio was significantly lower compared with positive controls (both, P < 0.05); this effect was not seen in the groups receiving 50 or 200 mg/kg daily. In experiment 2, prostatic weight and prostatic/body weight ratio in the group receiving D-004 were similar to those of positive controls. Body weight was not affected in any of the groups receiving D-004.
Conclusions:
This study of rats with T- or DHT-induced PH suggests that D-004 at 200 to 800 mg/kg daily administered orally prevents T-induced PH, and that D-004 at 800 mg/kg daily does not prevent DHT-induced PH.
Key words: benign prostatic hypertrophy, testosterone, prostatic enlargement, dihydrotestosterone
Full Text
The Full Text of this article is available as a PDF (433.6 KB).
References
- 1.Irani J, Brown CT, van der Meulen J, Emberton M. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: Are all guidelines the same? BJU Int. 2003;92:937–942. doi: 10.1111/j.1464-410x.2003.04529.x. [DOI] [PubMed] [Google Scholar]
- 2.Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med. 1995;332:99–109. doi: 10.1056/NEJM199501123320207. [DOI] [PubMed] [Google Scholar]
- 3.Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ. 2001;323:1042–1046. doi: 10.1136/bmj.323.7320.1042. [published correction appears in BMJ. 2002;324:775] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 2004;14:1–6. doi: 10.1097/00042307-200401000-00001. [DOI] [PubMed] [Google Scholar]
- 5.Djavan B, Remzi M, Erne B. The pathophysiology of benign prostatic hyperplasia. Drug Today (Barc) 2002;38:867–876. doi: 10.1358/dot.2002.38.12.740205. [DOI] [PubMed] [Google Scholar]
- 6.Carson C, III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(Suppl 1):2–7. doi: 10.1016/s0090-4295(03)00045-1. [DOI] [PubMed] [Google Scholar]
- 7.Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A. 2002;41:412–424. doi: 10.1007/s00120-002-0230-2. [in German] [DOI] [PubMed] [Google Scholar]
- 8.Sandhu JS, Te AE. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep. 2004;5:274–279. doi: 10.1007/s11934-004-0050-6. [DOI] [PubMed] [Google Scholar]
- 9.Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-Year follow-up. Urology. 2003;61:354–358. doi: 10.1016/s0090-4295(02)02149-0. [DOI] [PubMed] [Google Scholar]
- 10.Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029–1035. doi: 10.1097/01.ju.0000097026.43866.cc. [DOI] [PubMed] [Google Scholar]
- 11.Kirby RS, Roehrborn CG, Boyle P. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119–126. doi: 10.1016/s0090-4295(02)02114-3. [DOI] [PubMed] [Google Scholar]
- 12.McConnell JD, Roehrborn CG, Bautista OM. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;18:2387–2398. doi: 10.1056/NEJMoa030656. [DOI] [PubMed] [Google Scholar]
- 13.Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha-reductase inhibitors and alpha blockade: A reflection from MTOPS. Curr Opin Urol. 2004;14:17–20. doi: 10.1097/00042307-200401000-00004. [DOI] [PubMed] [Google Scholar]
- 14.Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr Ther Res Clin Exp. 1995;56:796–817. [Google Scholar]
- 15.Carraro JC, Raynaud JP, Koch G. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate. 1996;29:231–240. doi: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
- 16.Rhodes L, Primka RL, Berman C. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate. 1993;22:43–51. doi: 10.1002/pros.2990220107. [DOI] [PubMed] [Google Scholar]
- 17.Bombardelli E, Morazzoni P, Small JK. Serenoa repens (Bartram) Fitoterapia. 1997;68:99–113. [Google Scholar]
- 18.Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–395. doi: 10.2165/00002512-199609050-00008. [DOI] [PubMed] [Google Scholar]
- 19.Wilt TJ, Ishani A, Stark G. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA. 1998;280:1604–1609. doi: 10.1001/jama.280.18.1604. [DOI] [PubMed] [Google Scholar]
- 20.Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67:1281–1283. [PubMed] [Google Scholar]
- 21.Goepel M, Hecker U, Krege S. Saw palmetto extracts potently and non-competitively inhibit human alpha 1-adrenoceptors in vitro. Prostate. 1999;38:208–215. doi: 10.1002/(sici)1097-0045(19990215)38:3<208::aid-pros5>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- 22.Marks LS, Partin AW, Epstein JI. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163:1451–1456. [PubMed] [Google Scholar]
- 23.Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol. 1990;66:639–641. doi: 10.1111/j.1464-410x.1990.tb07199.x. [DOI] [PubMed] [Google Scholar]
- 24.Laguna A, Rodríguez E, González V, et al, inventors; Laboratorios Dalmer SA, assignee. Pharmaceutical composition and procedure for the prevention and treatment of prostate hyperplasia and prostatitis obtained from the fruits of Roystonea regia (Cuban royal palm). Cuba patent PCT/CU/2004/00004 (pending).
- 25.Arruzazabala ML, Carbajal D, Mas R, et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Rostonea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exptl Res. In press. [PubMed]
- 26.Nakayama O, Hirosumi J, Chida N. FRI46687, a novel steroid 5 alpha-reductase inhibitor: In vitro and in vivo effects on prostates. Prostate. 1997;31:241–249. doi: 10.1002/(sici)1097-0045(19970601)31:4<241::aid-pros5>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
- 27.Pandita RK, Persson K, Hedlund P, Andersson KE. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate. 1998;35:102–108. doi: 10.1002/(sici)1097-0045(19980501)35:2<102::aid-pros3>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
- 28.Paubert-Braquet M, Richardson FO, Servent-Saez N. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res. 1996;34:171–179. doi: 10.1006/phrs.1996.0085. [DOI] [PubMed] [Google Scholar]
- 29.Mahapokai W, Van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2000;3:28–33. doi: 10.1038/sj.pcan.4500391. [DOI] [PubMed] [Google Scholar]
- 30.Habib FK, Ross M, Bayne CW. Development of a new in vitro model for the study of benign prostatic hyperplasia. Prostate Suppl. 2000;9:15–20. doi: 10.1002/1097-0045(2000)45:9+<15::aid-pros4>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- 31.Tutrone RF, Jr, Ball RA, Ornitz DM. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model. J Urol. 1993;149:633–639. doi: 10.1016/s0022-5347(17)36169-4. [DOI] [PubMed] [Google Scholar]
- 32.Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 1992;88:15–22. doi: 10.1016/0303-7207(92)90004-p. [DOI] [PubMed] [Google Scholar]
- 33.Zhou ZX, Lane MV, Kemppainen JA. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol. 1995;9:208–218. doi: 10.1210/mend.9.2.7776971. [DOI] [PubMed] [Google Scholar]
